INFINITY-VENTURES
In response to the impact of COVID-19 on European communities, Lake House Group Chairman Charles Brown has donated and coordinated delivery of 2.5 million masks to three European nations in order to stem the spread of the virus. He said “Masks are a low-cost, effective intervention for stopping the spread of the virus and getting people back to work safely.”
A Hong Kong native with European roots, Brown has donated one million masks each to the Kingdom of Spain and the Federal Republic of Germany, with an additional 500,000 masks designated for Région Sud in France. “The masks landed in Spain and Germany on 15 and 19 April, respectively, and the masks bound for southern France are currently in transit,” reported Torsten Hartmann, Managing Director for Europe in Lake House’s London office.
While traveling in Europe prior to widespread lockdowns, Brown noted with concern that few European citizens wore masks in public. Regarding Hong Kong’s low number of confirmed cases since the outbreak began there on 23 January, Brown stated “The 2003 SARS epidemic taught Hong Kongers to be vigilant about wearing masks, and that experience shows.”
The donation efforts have been spearheaded by Brian Lu, Venture Partner at the Japanese venture capital firm Infinity Ventures, in which Charles Brown is a Limited Partner. The firm’s portfolio company, Hong Kong-based logistics startup Buyandship, has worked to ensure the masks are delivered with as little burden as possible on the governments receiving the donations.
According to Lu, “We’ve seen how tough it’s been for governments to obtain masks from trusted sources and get them delivered efficiently, so we’re proud to be able to help these countries get masks into people’s hands as quickly as possible.”
“Giving money is an easy thing if you have it, but a more effective thing is to deliver the goods to the point where they are needed, and that’s what we’re trying to achieve here,” added Lake House’s Charles Brown. “I hope our efforts are able to spark other private donors to use their resources and connections to make similar efforts,” he said.
About Lake House Group
Established in 1995, Lake House Group is a private investment company founded by Hong Kong native Charles Brown, who is also Chairman Emeritus and Founding Board Member of the United Nations Peace Development Foundation in China. Lake House is led by CEO David Timblick, and invests in businesses across the globe at every stage. With offices in Hong Kong and London, the firm is involved in projects and investments in excess of US$15 billion across 15 countries.
About Infinity Ventures
Infinity Ventures is a venture capital firm, focused on early stage Internet companies, founded in Japan in 2008, with offices in Tokyo, Taipei, and Beijing. The firm manages $255M USD, and has invested in 91 startups and produced 9 IPOs. Since its founding, Infinity Ventures has grown alongside its portfolio companies to build category-leading innovators and unicorns including Groupon, Farfetch, freee, Yeahka, WealthNavi, and 17 Media.
About Buyandship
Buyandship is a cross-border e-commerce logistics company established in 2014. The company provides a one-stop transit service for goods bought in the United States, United Kingdom, Japan, Korea, and China. Buyandship currently maintains warehouses in multiple countries, with daily scheduled flights to Hong Kong and other markets in Asia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200428006110/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom